Hepatocellular Carcinoma
Conditions
Keywords
Biobank analyses, Effect evaluation of the drug, patient-derived cells, SIRPα/CD47 expression
Brief summary
project is to study and develop anti-Signal Regulatory Protein α (SIRPα) antibodies (Ab) as a new immunotherapy strategy in cancer. Samples harvested from hepatocellular carcinoma (HCC) and ovarian cancer patients will be used in evaluation of the SIRP-CD47 expression and of the effect of the anti-human Signal Regulatory Protein (hSIRP) Ab on various cellular types from patients and healthy volunteers.
Interventions
PROCEDURECollection of human samples
Several types of samples will be used to test the effect of the drug candidate
Sponsors
Nantes University Hospital
Institut National de la Santé Et de la Recherche Médicale, France
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* adult * HCC patients (all BCLC stages accepted) * patient consent for the use of their biological samples
Exclusion criteria
* patient with other cancers * hepatitis C or B positive * HCC treatment by chemo-embolization under 3 months * under Sorafenib treatment within the month prior to collection * underage or under guardianship patients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| evaluation of the SIRP/CD47 expression | baseline | samples harvested from HCC and ovarian cancer patients will be used in evaluation of the SIRP-CD47 expression and of the effect of the anti-hSIRP Ab on various cellular types from patients |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORIsabelle ARCHAMBEAUD, Dr
Nantes University Hospital
Outcome results
None listed